β-Blockers and erectile dysfunction: more questions than answers

July 30, 2018
1167
Resume

The article deals with the problem of the possible development of erectile function disorders in patients with arterial hypertension who receive antihypertensive therapy. The causes of erectile dysfunction, as well as drugs, which are associated with its development, are named. The results of researches on the problem are presented. The analysis of literature data shows that there are significant contradictions in this regard.

L.L. Sidorova

Key words: arterial hypertension, erectile dysfunction, β-blockers.

Published: 04.09.2018

References:

  • Vertkin A.L. (2003) Erektilnaya disfunktsiya v praktike vracha-kardiologa. RMZh (Russkiy meditsinskiy zhurnal), 11(19): 1107–1113.
  • Andersen P., Seljeflot I., Herzog A. et al. (1998) Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men. J. Cardiovasc. Pharmacol., 31(5): 677–683.
  • Balshem H., Helfand M., Schünemann H.J. et al. (2011) GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol., 64(4): 401–406.
  • Bansal S. (1988) Sexual dysfunction in hypertensive men. A critical review of the literature. Hypertension, 29: 1–10.
  • Billups K.L., Edina M.N., Kaiser D. et al. (2003) Erectile dysfunction as an early indicator of systemic oxidative stress and endothelial cell dysfunction. J. Urol., 169: 323.
  • Botros S.M., Hussein A.M., Elserafy A.S. (2015) Effect of different beta blockers on penile vascular velocities in hypertensive males. Egypt. J. Soс. Radiol. Nucl. Med., 46(30): 749–754.
  • Broekman C.P., Haensel S.M., Van de Ven L.L., Slob A.K. (1992) Bisoprolol and hypertension: effects on sexual functioning in men. J. Sex. Marital. Ther., 18(4): 325–331.
  • Cocco G. (2009) Erectile dysfunction after therapy with metoprolol: The Hawthorne effect. Cardiology, 112: 174–177.
  • Cordero A., Bertomeu‐Martínez V., Mazón P. et al. (2010) Erectile dysfunction in high‐risk hypertensive patients treated with beta‐blockade agents. Cardiovasc. Ther., 28: 15–22.
  • Croog S.H., Levine S., Testa M.A et al. (1986) The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med., 314(26): 1657.
  • DeBusk R., Drory Y., Goldstein I. et al. (2000) Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am. J. Cardiol., 86(2A): 62F–68F.
  • Dong J.Y., Zhang Y.H., Qin L.Q. (2011) Erectile dysfunction and risk of cardiovascular disease: metaanalysis of prospective cohort studies. J. Am. Coll. Cardiol., 58: 1378–1385.
  • Drory Y., Shapira I., Fisman E.Z., Pines A. (1995) Myocardial ischemia during sexual activity in patients with coronary artery disease. Am. J. Cardiol., 75: 835–837.
  • eHealthMe (2018) Bisoprolol fumarate and Erectile dysfunction — from FDA reports (www.ehealthme.com/ds/bisoprolol-fumarate/erectile-dysfunction/).
  • Fauzan F., Irawan B., Hariawan H. (2016) Bisoprolol Therapy and The Risk of Erectile Dysfunction in Stable Coronary Artery Disease Patients. Acta Cardiol.Indones., 2(2): 56–60.
  • Feldman H.A., Goldstein I., Hatzichristou D.G. et al. (1994) Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J. Urol., 151: 54–61.
  • Ferini-Strambi L., Zucconi M., Rigatti P. et al. (1992) Male impotence: a possible beta-adrenergic dysfunction in some patients. Eur. Urol., 21: 332–334.
  • Fogari R., Preti P., Derosa G. et al. (2002) Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur. J. Clin. Pharmacol., 58: 177–180.
  • Goldstein I. (2000) The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction.Am. J. Cardiol., 86(2A): 41F–45F.
  • Gupta B.P., Murad M.H., Clifton M.M. et al. (2011) The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and metaanalysis. Arch. Intern. Med., 171: 1797–1803.
  • Jackson G., Betteridge J., Dean J. et al. (2002) A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement. Update 2002. Int. J. Clin. Pract., 56: 633–671.
  • Johannes C.B., Araujo A.B., Feldman H.A. et al. (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J. Urol., 163(2): 460–463.
  • Kaiser D.R., Billups K., Mason C. et al. (2004) Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J. Am. Coll. Cardiol., 43(2): 179–184.
  • Kawanishi Y., Lee K.S., Kimura K. et al. (2001) Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunctional patients. Int. J. Impot. Res., 13(2): 100–103.
  • Khan M.A., Morgan R.J., Mikhailidis D.P. (2002) The choice of antihypertensive drugs in patients with erectile dysfunction. Curr. Med. Res. Opin., 18: 103–107.
  • Kloner R.A., Speakman M. (2002) Erectile dysfunction and atherosclerosis. Curr. Atheroscler. Rep., 4(5): 397–401.
  • Ko D.T., Hebert P.R., Coffey C.S. et al. (2002) Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA, 288(3): 351–357.
  • Kostis J.B., Rosen R..C, Holzer B.C. et al. (1990) CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berlin), 102: 163–170.
  • Lue T.F. (2000) Erectile Dysfunction. N. Engl. J. Med., 342(24): 1802–1813.
  • Mancia G., Fagard R., Narkiewicz K. et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J., 34(28): 2159–2219.
  • Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Br. Med. J., 291: 97–104.
  • Muller J.E., Mittleman A., Maclure M. et al. (1996) Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA, 275: 1405–1409.
  • NIH Consensus Conference (1993) NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. 270(1): 83–90.
  • Palmore E.B. (1982) Predictors of the longevity difference: a 25-year follow-up. Gerontologist, 22: 513–518.
  • Parazzini F., Menchini F.F., Bortolotti A. et al. (2000) Frequency and determinants of erectile dysfunction in Italy. Eur. Urol., 37: 43–49.
  • Parzeller M., Raschka C., Bratzke H. (2000) Sudden cardiovascular death in correlation with sexual activity: results of a medicolegal postmortem study from 1972–1998. Eur. Heart J., 22: 610–611.
  • Persson G. (1981) Five-year mortality in a 70-year-old urban population in relation to psychiatric diagnosis, personality, sexuality am early parental death. Acta Psychiatr. Scand., 64: 244–253.
  • Pickering T.G., Shepherd A.M., Puddey I. et al. (2004) Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am. J. Hypertens., 17: 1135–1142.
  • Prisant L.M. (2002) Fixed low-dose combination in first-line treatment of hypertension. J. Hypertens., 20(1): S11–S19.
  • Selvin E., Burnett A.L., Platz E.A. (2007) Prevalence and risk factors for erectile dysfunction in the US. Am. J. Med., 120: 151–157.
  • Sharp R.P., Gales B.J. (2017) Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. Ther. Adv. Urol., 9(2): 59–63.
  • Silvestri A., Galetta P., Cerquetani E. et al. (2003) Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur. Heart J., 24(21): 1928–1932.
  • Smith D.G., Frankel S., Yamell J. (1997) Sex and death: are they related? Findings from the Caerphilly Cohort Study. BMJ, 315: 1641–1644.
  • Smith E.R., Cetrulo E.J., Donahue J.P. et al. (1995) The inhibitory effects of propranolol on genital reflexes in male rats. Pharmacol. Biochem. Behav., 52: 541–546.
  • Solomon H., Man J.W., Jackson G. (2003) Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart, 89(3): 251–253.
  • Speel T.G., van Langen H., Meuleman E.J. (2003) The risk of coronary heart disease in men with erectile dysfunction. Eur. Urol., 44(3): 366–371.